Key result
ICI therapy yields complete metabolic response in a patient with intracardiac metastatic sarcoma over 2 years.
Why the study?
Intracardiac metastases causing right ventricular outflow tract obstruction carry a dismal prognosis, and immune checkpoint inhibitor therapy risks pseudoprogression that could worsen hemodynamic obstruction.
Does immune checkpoint inhibitor therapy with multimodality imaging monitoring improve outcomes in a patient with intracardiac metastatic sarcoma causing right ventricular outflow tract obstruction?
Case Report (n=1)
Does immune checkpoint inhibitor therapy with multimodality imaging monitoring improve outcomes in a patient with intracardiac metastatic sarcoma causing right ventricular outflow tract obstruction?
Multimodality imaging and multidisciplinary cardio-oncology collaboration can enable safe delivery and monitoring of immune checkpoint inhibitor therapy in patients with hemodynamically significant intracardiac metastatic disease.
Hypothesis-generating for immunotherapy in intracardiac sarcoma; prospective trials needed to confirm safety and efficacy.
BACKGROUND: Intracardiac metastases causing right ventricular outflow tract obstruction are rare and carry a dismal prognosis. Immune checkpoint inhibitor (ICI) therapy risks immune-mediated pseudoprogression that could worsen hemodynamic obstruction. CASE SUMMARY: A 40-year-old man with metastatic alveolar soft part sarcoma presented with dyspnea, pericardial effusion, and intracardiac masses causing significant right ventricular outflow tract obstruction. Cardiac magnetic resonance tissue characterization established a noninvasive diagnosis without endomyocardial biopsy. ICI therapy was delivered as an inpatient in a coronary care unit with continuous cardiology monitoring. Serial echocardiography demonstrated progressive reduction in mass size with relief of obstruction, and Cardiac magnetic resonance confirmed treatment response. More than 2 years later, he achieved complete metabolic response on positron emission tomography-computed tomography and remains well in active surveillance. DISCUSSION: Multimodality imaging provides complementary hemodynamic, tissue-level, and metabolic surveillance essential for detecting pseudoprogression and confirming true treatment response in hemodynamically significant intracardiac tumors. TAKE-HOME MESSAGE: Multidisciplinary cardio-oncology collaboration can enable safe ICI delivery and durable complete response in hemodynamically significant intracardiac metastatic disease.
No takes yet. Share an insight, caveat, or question.
Kocx et al. (2026) conducted a case report in Metastatic alveolar soft part sarcoma with intracardiac metastases (n=1). Immune checkpoint inhibitor (ICI) therapy was evaluated on Treatment response. Immune checkpoint inhibitor therapy led to progressive reduction in mass size and complete metabolic response at >2 years in a 40-year-old man with intracardiac metastatic sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: